Last year, as coronavirus stocks became a thing, Inovio Pharmaceuticals (INO) was one of the early front runners, and investors pinned hopes on the biotech’s potential Covid-19 DNA vaccine INO-4800. But the company has been unable to complete its program while others have progressed passed regulatory hurdles and brought their respective vaccines to market. In fact, the phase 3 portion of the U.S. trial is still on hold, as questions still remain regarding the proprietary delivery device via which the vaccine is administered. Following the FDA’s halt, the government also pulled the plug on the funding of INO-4800’s development.
https://www.tipranks.com/news/article/inovio-covid-19-vaccine-opportunity-still-at-play?utm_source=advfn.com&utm_medium=referral
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Inovio Pharmaceuticals Charts.